| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Targets G protein-coupled receptor 68 (GPR68, also known as OGR1), a proton-sensing GPCR. Ogremorphin acts as a potent inhibitor (antagonist) of this receptor with an EC50 of 170 nM. By blocking GPR68, it inhibits the cellular signaling pathways that are normally activated by acidic pH.
|
|---|---|
| ln Vitro |
In vitro, Ogremorphin has been shown to inhibit the migration of human melanoma cells, demonstrating an anti-metastatic effect. It also induces ferroptosis, a form of regulated cell death, in glioblastoma cells. These in vitro activities highlight its potential for cancer research, particularly in the context of the acidic tumor microenvironment.
|
| ln Vivo |
Detailed in vivo activity data is limited, but the compound has been developed for research on autoimmune chronic inflammatory diseases. As a GPR68 inhibitor, it has the potential for use in animal models of inflammation, where blocking the receptor‘s response to tissue acidosis could reduce pain, vascular permeability, and immune cell infiltration, providing therapeutic benefit.
|
| Enzyme Assay |
Since Ogremorphin is an antagonist, non-cell radioligand binding assays for GPR68 can be performed. Membranes from cells overexpressing GPR68 are incubated with a radiolabeled agonist and increasing concentrations of the antagonist. Bound radioactivity is separated by filtration and counted to determine its binding affinity and to calculate the IC50.
|
| Cell Assay |
Functional cell-based assays for GPR68 inhibition are performed by measuring the blockade of pH-dependent signaling. Cells expressing GPR68 are loaded with a calcium-sensitive dye. The cells are pre-incubated with Ogremorphin and then challenged with an acidic pH (e.g., pH 6.5). The reduction in the resulting calcium flux compared to vehicle control is measured to determine the antagonist‘s potency (EC50 = 170 nM).
|
| Animal Protocol |
No specific animal studies for Ogremorphin are publicly available. A potential in vivo model would be a mouse model of inflammatory pain, such as the complete Freund‘s adjuvant (CFA)-induced inflammatory pain model. Ogremorphin could be administered systemically, and endpoints would include measuring mechanical allodynia and thermal hyperalgesia, as well as paw edema and inflammatory cytokine levels.
|
| ADME/Pharmacokinetics |
Detailed PK data for Ogremorphin is not publicly available. As a small molecule with a molecular weight of 359.44, it may have potential for oral activity, though no formal PK studies have been published. It is soluble in DMSO, and its in vivo formulation would need to be optimized for preclinical studies.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is publicly available for Ogremorphin. As a research-grade antagonist, no safety studies have been published. Its pharmacological mechanism of blocking GPR68, a pH sensor, may be involved in normal physiological processes like bone formation and endothelial function, so its long-term inhibition could potentially have effects.
|
| References |
[1]. Charles C. Hong, et al. Small molecule inhibitors of gpcr gpr68 and related receptors. Patent WO2020214896.
|
| Additional Infomation |
Ogremorphin is a research-grade chemical and is not approved for clinical use. It is a valuable tool for studying the pathophysiological roles of the GPR68 receptor. This receptor is an emerging drug target for cancer (due to its role in the acidic tumor microenvironment), chronic pain, and autoimmune diseases like rheumatoid arthritis and colitis.
|
| Molecular Formula |
C21H17N3OS
|
|---|---|
| Molecular Weight |
359.444183111191
|
| Exact Mass |
359.109
|
| CAS # |
352563-21-4
|
| PubChem CID |
2861516
|
| Appearance |
Yellow to orange solid powder
|
| LogP |
5.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
608
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC1=CC2=C(C=C1)NC(=O)C23NN=C(S3)C4=CC=CC5=CC=CC=C54
|
| InChi Key |
FXTVKHHEAAQZHM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H17N3OS/c1-2-13-10-11-18-17(12-13)21(20(25)22-18)24-23-19(26-21)16-9-5-7-14-6-3-4-8-15(14)16/h3-12,24H,2H2,1H3,(H,22,25)
|
| Chemical Name |
5-ethyl-5'-naphthalen-1-ylspiro[1H-indole-3,2'-3H-1,3,4-thiadiazole]-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7821 mL | 13.9105 mL | 27.8211 mL | |
| 5 mM | 0.5564 mL | 2.7821 mL | 5.5642 mL | |
| 10 mM | 0.2782 mL | 1.3911 mL | 2.7821 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
